about
Acetazolamide: a second wind for a respiratory stimulant in the intensive care unit?Population pharmacodynamic modeling and simulation of the respiratory effect of acetazolamide in decompensated COPD patientsPharmacokinetics and Toxicity in Rats and Monkeys of coDbait: A Therapeutic Double-stranded DNA Oligonucleotide Conjugated to CholesterolPharmacokinetics, hemodynamic and metabolic effects of epinephrine to prevent post-operative low cardiac output syndrome in childrenPopulation pharmacokinetics of emtricitabine in HIV-1-infected adult patientsContribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy.Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?Population pharmacokinetics of abacavir in pregnant women.Population pharmacokinetics of nevirapine in HIV-1-infected pregnant women and their neonates.Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.Evaluation of effect of impaired renal function on lamivudine pharmacokineticsPopulation pharmacokinetics and haemodynamic effects of norepinephrine in hypotensive critically ill children.Determination of optimal vitamin D3 dosing regimens in HIV-infected paediatric patients using a population pharmacokinetic approach.Modified renal function in pregnancy: impact on emtricitabine pharmacokinetics.Maternal and fetal zidovudine pharmacokinetics during pregnancy and labour: too high dose infused at labour?Influence of body weight on achieving indinavir concentrations within its therapeutic window in HIV-infected Thai patients receiving indinavir boosted with ritonavir.Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women.Impact of body weight and missed doses on lopinavir concentrations with standard and increased lopinavir/ritonavir doses during late pregnancy.Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2Lopinavir/ritonavir population pharmacokinetics in neonates and infants.Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2).Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2)Weekly administration of paclitaxel: theoretical and clinical basis.Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents.No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 yearsPharmacokinetics and virological efficacy after switch to once-daily lopinavir-ritonavir in treatment-experienced HIV-1-infected childrenModeling of In-Utero and Intra-Partum Transmissions to Evaluate the Efficacy of Interventions for the Prevention of Perinatal HIV.Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patientsPregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women.Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis.Population pharmacodynamic model of bicarbonate response to acetazolamide in mechanically ventilated chronic obstructive pulmonary disease patients.Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study.Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients.Pharmacokinetic modelling of the placental transfer of nelfinavir and its M8 metabolite: a population study using 75 maternal-cord plasma samples.
P50
Q27023730-AA96F665-08E9-4F96-A107-E94B8A231E26Q28538832-4C06703E-6202-414B-96C9-105BF4558DC7Q30523973-3F2C2FD4-9796-4D9C-928F-F9A737BCB61CQ30580672-06EF8F94-5881-4D80-B2A1-5ED8DB7A71A2Q33622825-483FBCEA-BC5F-4682-8000-F28EF1855F97Q33714594-3C70A0A3-AEAA-4C8D-B6FC-E466B45A443AQ33938112-8A3B82DF-2031-4F29-A6F5-9ED71C6988BFQ34045390-94346B49-40C2-4137-9F48-E4E45E5DBB4BQ34299084-D04BBF93-47C1-44F3-AF11-69517DCBFA3AQ34483505-9225AC93-52FC-4D89-8D54-F9618E338585Q34509618-72D28EB7-AEA7-4FB5-837F-3397897CBF7FQ34554449-D6767726-FA67-4F65-83B3-B9BCA70CE00BQ34554480-1715DB3E-6A1F-46A9-89D7-019855AE2138Q34570942-3E231B12-262A-43FB-BBB8-D8967A0133DEQ34635554-7ED647F9-D11C-4136-AED1-AD0B75278393Q34635561-E4FA8EDD-6562-4188-AC8C-CC965D2F0A7CQ34677780-2C614BEA-FA86-4AE4-99E3-062A7CAA4D13Q34680529-EC6592FA-A5E6-400A-9930-171090307780Q34710705-CDDA0F54-64E5-41FD-AF66-69F4B6A83266Q34737231-22512E50-8FD8-43A8-AF14-2B6B9324C0D7Q34996974-C74857DD-ACBF-4168-A32B-FEB0C30EB29DQ35004837-876B8BED-C745-4666-9481-C6828980CFB5Q35005051-0F7AC80E-1EDE-4FA3-8DE2-CCAB1C83EB59Q35035771-7C004E1D-9F6F-4874-A81A-B46CCB1E3B31Q35065937-87391B1D-4B57-42C3-85E6-37D05B7031B1Q35102254-CFDF6201-A8C4-4F6E-8FE4-7CEA6022ADAEQ35127775-21CC8A98-62FB-448C-BF7D-92E7E27DFFC3Q35191590-BC04F202-92BB-4F8F-B565-0CFC7F54CE5EQ35625548-C1727172-0C84-497A-8B9F-0EE34A5C134FQ35629777-5D068A7E-510C-4FDB-A893-D7DF46B7D3A9Q35669764-9C92769E-E88C-4213-9295-B2F251F9081CQ35689342-7EE6C482-6BEA-4175-B854-6789B74A4E4CQ35689404-ECD8F505-E45C-4901-9926-2372843BB85DQ35826954-0E366BAE-6E0B-4D33-B75E-F1E38D55032DQ35908114-3D885DB5-B157-4C0E-8419-06E6286903A7Q35960706-2CA0F5B8-9A26-490A-BCF8-1E8465C05D62Q36158516-EBAB7C5C-8358-4C91-8070-A48465D3985DQ36243626-1DFF3D13-5768-47B5-B2D5-3822D3159578Q36379884-9EBB988C-93BC-45DA-9B26-2049F85ADFD1Q36388061-B80ADA78-6DD8-49C7-890D-9774B7ECB1B1
P50
description
onderzoeker
@nl
name
Saïk Urien
@ast
Saïk Urien
@en
Saïk Urien
@sl
type
label
Saïk Urien
@ast
Saïk Urien
@en
Saïk Urien
@sl
altLabel
Saik Urien
@en
prefLabel
Saïk Urien
@ast
Saïk Urien
@en
Saïk Urien
@sl
P214
P106
P213
0000 0004 3233 6852
P214
P31
P7859
viaf-213194531